LY-3200882 Uses, Dosage, Side Effects and more
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
| Trade Name | LY-3200882 |
| Generic | LY-3200882 |
| Type | |
| Formula | C24H29N5O3 |
| Weight | Average: 435.528 Monoisotopic: 435.227039814 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
